Browsing Tag
Ovarian Cancer
32 posts
BiVictriX Therapeutics secures Innovate UK grant to advance ovarian cancer treatment
BiVictriX Therapeutics plc (AIM: BVX), a pioneering drug discovery and development company, has announced receiving a substantial grant…
June 7, 2024
LIXTE Biotechnology commences Phase 1b/2 clinical trial in ovarian cancer
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) has initiated a pivotal Phase 1b/2 clinical trial, in partnership…
January 29, 2024
Zydus Lifesciences gains FDA approval for Cyclophosphamide Capsules
Zydus Lifesciences Limited, a leading pharmaceutical company, has achieved a significant milestone by receiving final approval from the…
December 17, 2023
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 “ELUCIDATE” study, marking the first trial…
July 11, 2023
ImmunoGen secures up to $175m from Pharmakon Advisors to accelerate oncology growth
ImmunoGen secures up to $175M in non-dilutive funding from Pharmakon to fuel Elahere’s launch and expand its next-gen ADC pipeline. Read the full breakdown.
April 8, 2023
TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial
TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial…
September 18, 2021
Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy
Anixa Biosciences said that it has filed an investigational new drug (IND) application for its ovarian cancer CAR-T…
March 22, 2021
Chinese regulator accepts NDA of BeiGene’s pamiparib in ovarian cancer
BeiGene said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has…
July 19, 2020
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused…
February 10, 2019
Clovis Oncology secures EC approval for Rubraca’s new indication in ovarian cancer treatment
In a major win for Clovis Oncology, the European Commission (EC) has granted approval for an expanded indication…
January 26, 2019